TrovaGene Stock Price, News & Analysis (NASDAQ:TROV)

$0.34 -0.01 (-2.86 %)
(As of 01/16/2018 08:40 AM ET)
Previous Close$0.35
Today's Range$0.32 - $0.35
52-Week Range$0.23 - $2.40
Volume454,800 shs
Average Volume1.83 million shs
Market Capitalization$17.84 million
P/E Ratio-0.35
Dividend YieldN/A
Beta0.4

About TrovaGene (NASDAQ:TROV)

TrovaGene logoTrovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.

Receive TROV News and Ratings via Email

Sign-up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic & Testing Substances
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:TROV
CUSIPN/A
Phone+1-858-2175420

Debt

Debt-to-Equity RatioN/A
Current Ratio1.68%
Quick Ratio1.68%

Price-To-Earnings

Trailing P/E Ratio-0.346938775510204
Forward P/E Ratio-0.44
P/E GrowthN/A

Sales & Book Value

Annual Sales$380,000.00
Price / Sales47.23
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book0.52

Profitability

Trailing EPS($0.98)
Net Income$-39,200,000.00
Net Margins-7,960.05%
Return on Equity-259.94%
Return on Assets-95.96%

Miscellaneous

Employees53
Outstanding Shares52,790,000

TrovaGene (NASDAQ:TROV) Frequently Asked Questions

What is TrovaGene's stock symbol?

TrovaGene trades on the NASDAQ under the ticker symbol "TROV."

How were TrovaGene's earnings last quarter?

TrovaGene Inc (NASDAQ:TROV) announced its quarterly earnings data on Thursday, November, 9th. The medical research company reported ($0.12) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.02. The medical research company had revenue of $0.12 million for the quarter. TrovaGene had a negative net margin of 7,960.05% and a negative return on equity of 259.94%. View TrovaGene's Earnings History.

When will TrovaGene make its next earnings announcement?

TrovaGene is scheduled to release their next quarterly earnings announcement on Tuesday, March, 13th 2018. View Earnings Estimates for TrovaGene.

Where is TrovaGene's stock going? Where will TrovaGene's stock price be in 2018?

4 analysts have issued 1-year price objectives for TrovaGene's shares. Their predictions range from $1.00 to $8.00. On average, they expect TrovaGene's stock price to reach $3.70 in the next year. View Analyst Ratings for TrovaGene.

Who are some of TrovaGene's key competitors?

Who are TrovaGene's key executives?

TrovaGene's management team includes the folowing people:

  • Thomas H. Adams Jr. Ph.D., Chairman of the Board (Age 74)
  • William J. Welch, Chief Executive Officer, Director (Age 54)
  • Athena M. Countouriotis M.D., Director (Age 45)
  • Paul R. Billings M.D. Ph.D., Independent Director (Age 63)
  • John P. Brancaccio CPA, Independent Director (Age 69)
  • Gary S. Jacob Ph.D., Independent Director (Age 70)
  • Rodney S. Markin M.D., Ph.D., Independent Director (Age 58)

Who owns TrovaGene stock?

TrovaGene's stock is owned by many different of institutional and retail investors. Top institutional shareholders include INTRACOASTAL CAPITAL, LLC (4.80%) and INTRACOASTAL CAPITAL, LLC (4.80%). Company insiders that own TrovaGene stock include Mark Erlander, Stanley Tennant and William J Welch. View Institutional Ownership Trends for TrovaGene.

How do I buy TrovaGene stock?

Shares of TrovaGene can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TrovaGene's stock price today?

One share of TrovaGene stock can currently be purchased for approximately $0.34.

How big of a company is TrovaGene?

TrovaGene has a market capitalization of $17.84 million and generates $380,000.00 in revenue each year. The medical research company earns $-39,200,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. TrovaGene employs 53 workers across the globe.

How can I contact TrovaGene?

TrovaGene's mailing address is 11055 Flintkote Ave, SAN DIEGO, CA 92121-1220, United States. The medical research company can be reached via phone at +1-858-2175420 or via email at [email protected]


MarketBeat Community Rating for TrovaGene (TROV)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  205 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  322
MarketBeat's community ratings are surveys of what our community members think about TrovaGene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

TrovaGene (NASDAQ:TROV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.252.002.332.33
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.70$4.60$4.60$4.45
Price Target Upside: 1,380.00% upside576.47% upside482.28% upside277.12% upside

TrovaGene (NASDAQ:TROV) Consensus Price Target History

Price Target History for TrovaGene (NASDAQ:TROV)

TrovaGene (NASDAQ:TROV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/21/2017HC WainwrightInitiated CoverageBuy$1.00HighView Rating Details
11/10/2017Maxim GroupDowngradeBuy -> HoldN/AView Rating Details
8/8/2017Cantor FitzgeraldReiterated RatingOverweightHighView Rating Details
3/16/2017Piper Jaffray CompaniesDowngradeNeutral -> UnderweightHighView Rating Details
3/10/2017S&P Equity ResearchBoost Price Target$1.55 -> $1.80N/AView Rating Details
5/12/2016Leerink SwannReiterated RatingHoldN/AView Rating Details
4/28/2016ArgusDowngradeBuy -> HoldN/AView Rating Details
3/29/2016Avondale PartnersReiterated RatingMarket Perform$6.00N/AView Rating Details
3/11/2016Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
2/22/2016Jefferies GroupReiterated RatingBuyN/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

TrovaGene (NASDAQ:TROV) Earnings History and Estimates Chart

Earnings by Quarter for TrovaGene (NASDAQ:TROV)

TrovaGene (NASDAQ TROV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2018($0.12)N/AView Earnings Details
11/9/2017Q3 2017($0.14)($0.12)$0.12 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.14)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.26)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.29)($0.31)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.32)($0.34)ViewN/AView Earnings Details
8/4/2016Q2 2016($0.33)($0.34)ViewN/AView Earnings Details
5/10/2016Q116($0.29)($0.36)$0.34 million$0.12 millionViewListenView Earnings Details
3/10/2016Q415($0.25)($0.26)$0.14 million$0.08 millionViewListenView Earnings Details
11/9/2015Q3 2015($0.28)($0.37)ViewN/AView Earnings Details
8/10/2015Q215($0.24)($0.41)$0.05 millionViewListenView Earnings Details
5/5/2015($0.23)($0.24)$0.08 million$0.13 millionViewN/AView Earnings Details
3/12/2015Q414($0.26)($0.25)$0.06 millionViewN/AView Earnings Details
11/6/2014Q3 14($0.25)($0.28)$0.05 million$0.06 millionViewN/AView Earnings Details
8/7/2014($0.24)($0.18)$0.05 million$0.06 millionViewN/AView Earnings Details
5/12/2014($0.23)($0.17)$0.05 million$0.11 millionViewN/AView Earnings Details
3/17/2014Q413($0.19)($0.05)$0.15 million$0.05 millionViewN/AView Earnings Details
11/14/2013Q313($0.22)($0.25)ViewN/AView Earnings Details
8/14/2013Q213($0.15)($0.34)ViewN/AView Earnings Details
5/14/2013Q113($0.09)($0.07)$0.03 million$0.12 millionViewN/AView Earnings Details
4/1/2013Q1 2013($0.10)($0.10)ViewN/AView Earnings Details
11/14/2012Q4 2012($0.05)ViewN/AView Earnings Details
8/15/2012Q3 2012($0.28)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

TrovaGene (NASDAQ:TROV) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.78 EPS
Next Year EPS Consensus Estimate: $-0.31 EPS

Dividends

Dividend History for TrovaGene (NASDAQ:TROV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

TrovaGene (NASDAQ TROV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.40%
Institutional Ownership Percentage: 9.91%
Insider Trades by Quarter for TrovaGene (NASDAQ:TROV)
Institutional Ownership by Quarter for TrovaGene (NASDAQ:TROV)

TrovaGene (NASDAQ TROV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/5/2017Stanley TennantDirectorSell8,334$0.69$5,750.46209,394View SEC Filing  
12/19/2016Stanley TennantDirectorBuy10,000$2.10$21,000.00217,728View SEC Filing  
12/16/2016Stanley TennantDirectorBuy14,966$2.00$29,932.00207,728View SEC Filing  
12/16/2016William J WelchCEOBuy4,750$2.09$9,927.502,500View SEC Filing  
12/14/2016Mark ErlanderInsiderBuy5,000$2.08$10,400.005,000View SEC Filing  
8/12/2015Antonius SchuhCEOBuy20,000$5.45$109,000.00View SEC Filing  
8/12/2015Stanley TennantDirectorBuy10,000$6.06$60,600.00View SEC Filing  
8/12/2015Steve ZaniboniCFOBuy15,000$5.43$81,450.00View SEC Filing  
7/17/2015Bridger Management, LlcMajor ShareholderBuy140,000$8.75$1,225,000.00View SEC Filing  
4/2/2015Bridger Management, LlcMajor ShareholderBuy300,000$6.90$2,070,000.00View SEC Filing  
2/27/2015Bridger Management, LlcMajor ShareholderBuy263,286$5.36$1,411,212.96View SEC Filing  
2/6/2015Bridger Management, LlcMajor ShareholderBuy444,444$4.50$1,999,998.00View SEC Filing  
6/9/2014Steve ZaniboniCFOBuy6,329$3.95$24,999.55View SEC Filing  
9/3/2013Thomas Phd AdamsDirectorSell19,200$8.19$157,248.00View SEC Filing  
11/30/2012Stanley TennantDirectorBuy25,000$4.82$120,500.00View SEC Filing  
8/20/2012Gabriel CerroneDirectorBuy7,800$2.35$18,330.00View SEC Filing  
8/16/2012Gabriel CerroneDirectorBuy15,000$2.24$33,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

TrovaGene (NASDAQ TROV) News Headlines

Source:
DateHeadline
Should You Be Concerned About TrovaGene Inc’s (NASDAQ:TROV) Risks?Should You Be Concerned About TrovaGene Inc’s (NASDAQ:TROV) Risks?
finance.yahoo.com - January 8 at 3:32 PM
Form 4/A Trovagene, Inc. For: Jan 02 Filed by: WELCH WILLIAM JForm 4/A Trovagene, Inc. For: Jan 02 Filed by: WELCH WILLIAM J
www.streetinsider.com - January 5 at 9:24 AM
Trovagene to Present at the Biotech Showcase™ Annual Conference - PR Newswire (press release)Trovagene to Present at the Biotech Showcase™ Annual Conference - PR Newswire (press release)
www.prnewswire.com - January 3 at 3:27 PM
Trovagene to Present at the Biotech Showcase™ Annual ConferenceTrovagene to Present at the Biotech Showcase™ Annual Conference
finance.yahoo.com - January 3 at 11:01 AM
Is Now The Time To Bet On The Healthcare Sector And TrovaGene Inc (NASDAQ:TROV)?Is Now The Time To Bet On The Healthcare Sector And TrovaGene Inc (NASDAQ:TROV)?
finance.yahoo.com - January 1 at 3:28 PM
Trovagene (TROV) Reports Activation of Second Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075Trovagene (TROV) Reports Activation of Second Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075
www.streetinsider.com - December 22 at 8:52 PM
Will TrovaGene Inc’s (NASDAQ:TROV) Earnings Grow In The Years Ahead?Will TrovaGene Inc’s (NASDAQ:TROV) Earnings Grow In The Years Ahead?
finance.yahoo.com - December 22 at 3:52 PM
Trovagene Announces Activation of Second Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for ... - PR Newswire (press release)Trovagene Announces Activation of Second Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for ... - PR Newswire (press release)
www.prnewswire.com - December 21 at 3:30 PM
TrovaGene (TROV) Earns Buy Rating from Analysts at HC WainwrightTrovaGene (TROV) Earns Buy Rating from Analysts at HC Wainwright
www.americanbankingnews.com - December 21 at 3:06 PM
BRIEF-Trovagene Announces Activation Of Second Clinical Trial Site In Phase 1B/2 Acute Myeloid Leukemia TrialBRIEF-Trovagene Announces Activation Of Second Clinical Trial Site In Phase 1B/2 Acute Myeloid Leukemia Trial
www.reuters.com - December 21 at 9:04 AM
Trovagene Announces Activation of Second Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075Trovagene Announces Activation of Second Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075
finance.yahoo.com - December 21 at 9:04 AM
Mid-Day Market Update: ShiftPixy Gains Following Q4 Results; Verastem Shares PlummetMid-Day Market Update: ShiftPixy Gains Following Q4 Results; Verastem Shares Plummet
www.nasdaq.com - December 15 at 3:31 PM
Pre-Open Movers 12/15: (DDR) (ALNY) (HES) Higher; (TROV) (VSTM) (CSX) Lower (more...)Pre-Open Movers 12/15: (DDR) (ALNY) (HES) Higher; (TROV) (VSTM) (CSX) Lower (more...)
www.streetinsider.com - December 15 at 3:31 PM
Why TrovaGene Inc (TROV) Stock Tanked 40% TodayWhy TrovaGene Inc (TROV) Stock Tanked 40% Today
finance.yahoo.com - December 15 at 3:30 PM
Trovagene Prices $4.5 Million Public OfferingTrovagene Prices $4.5 Million Public Offering
finance.yahoo.com - December 15 at 9:06 AM
BRIEF-Trovagene Submits Protocol To FDA For Phase 2 Clinical Trial Of Pcm-075 In Combination With Zytiga®BRIEF-Trovagene Submits Protocol To FDA For Phase 2 Clinical Trial Of Pcm-075 In Combination With Zytiga®
www.reuters.com - December 14 at 3:28 PM
Technical Perspectives on TrovaGene, Accelerate Diagnostics, NeoGenomics, and Exact Sciences - PR Newswire (press release)Technical Perspectives on TrovaGene, Accelerate Diagnostics, NeoGenomics, and Exact Sciences - PR Newswire (press release)
www.prnewswire.com - December 14 at 9:01 AM
Trovagene (TROV) Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga for mCRPC - StreetInsider.comTrovagene (TROV) Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga for mCRPC - StreetInsider.com
www.streetinsider.com - December 14 at 9:01 AM
Trovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® for Metastatic Castration-Resistant Prostate CancerTrovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® for Metastatic Castration-Resistant Prostate Cancer
finance.yahoo.com - December 14 at 9:01 AM
Trovagene Announces the Launch of NextCollect™ Urine Collection and DNA Preservation Kit to Research ... - PR Newswire (press release)Trovagene Announces the Launch of NextCollect™ Urine Collection and DNA Preservation Kit to Research ... - PR Newswire (press release)
www.prnewswire.com - December 13 at 3:28 PM
Trovagene Announces the Launch of NextCollect™ Urine Collection and DNA Preservation Kit to Research Laboratories and Pharmaceutical CustomersTrovagene Announces the Launch of NextCollect™ Urine Collection and DNA Preservation Kit to Research Laboratories and Pharmaceutical Customers
finance.yahoo.com - December 12 at 8:56 AM
ETFs with exposure to TrovaGene, Inc. : December 11, 2017ETFs with exposure to TrovaGene, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:26 PM
Trovagene (TROV) Announces Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with ZytigaTrovagene (TROV) Announces Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga
www.streetinsider.com - December 8 at 3:27 PM
BRIEF-Trovagenes preclinical data to be featured at San Antonio Breast Cancer SymposiumBRIEF-Trovagene's preclinical data to be featured at San Antonio Breast Cancer Symposium
www.reuters.com - December 8 at 3:27 PM
BRIEF-Trovagenes preclinical data to be featured at San Antonio Breast Cancer SymposiumBRIEF-Trovagene's preclinical data to be featured at San Antonio Breast Cancer Symposium
www.reuters.com - December 8 at 3:27 PM
Trovagene Presents Data Showing Sensitivity of Triple Negative ... - PR Newswire (press release)Trovagene Presents Data Showing Sensitivity of Triple Negative ... - PR Newswire (press release)
www.prnewswire.com - December 8 at 9:11 AM
Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga® at San Antonio Breast Cancer Symposium (SABCS)Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga® at San Antonio Breast Cancer Symposium (SABCS)
finance.yahoo.com - December 8 at 9:11 AM
Interested In TrovaGene Inc (TROV)? Here’s What Its Recent Track-Record Looks LikeInterested In TrovaGene Inc (TROV)? Here’s What Its Recent Track-Record Looks Like
finance.yahoo.com - December 7 at 3:30 PM
ETFs with exposure to TrovaGene, Inc. : November 30, 2017ETFs with exposure to TrovaGene, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 3:27 PM
TrovaGene, Inc. :TROV-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017TrovaGene, Inc. :TROV-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 9:10 AM
What does TrovaGene Inc’s (TROV) Balance Sheet Tell Us Abouts Its Future?What does TrovaGene Inc’s (TROV) Balance Sheet Tell Us Abouts Its Future?
finance.yahoo.com - November 20 at 11:27 AM
TrovaGene, Inc. (TROV) Stock Rating Lowered by TrovaGene, Inc. (TROV) Stock Rating Lowered by
www.americanbankingnews.com - November 19 at 4:20 PM
Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM ... - PR Newswire (press release)Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM ... - PR Newswire (press release)
www.prnewswire.com - November 14 at 11:51 AM
Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075
finance.yahoo.com - November 14 at 11:51 AM
Trovagene Announces Third Quarter 2017 Company Highlights and Financial ResultsTrovagene Announces Third Quarter 2017 Company Highlights and Financial Results
finance.yahoo.com - November 12 at 12:39 PM
Trovagene reports 3Q lossTrovagene reports 3Q loss
finance.yahoo.com - November 12 at 12:39 PM
TrovaGene, Inc. (TROV) Cut to "Hold" at Maxim GroupTrovaGene, Inc. (TROV) Cut to "Hold" at Maxim Group
www.americanbankingnews.com - November 12 at 12:36 PM
TrovaGene, Inc. (TROV) Issues  Earnings Results, Beats Estimates By $0.02 EPSTrovaGene, Inc. (TROV) Issues Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - November 10 at 7:54 PM
Contrasting IRIS International (IRIS) and TrovaGene (TROV)Contrasting IRIS International (IRIS) and TrovaGene (TROV)
www.americanbankingnews.com - November 9 at 5:30 PM
ETFs with exposure to TrovaGene, Inc. : November 1, 2017ETFs with exposure to TrovaGene, Inc. : November 1, 2017
finance.yahoo.com - November 2 at 10:04 AM
TrovaGene, Inc. (TROV) Set to Announce Quarterly Earnings on TuesdayTrovaGene, Inc. (TROV) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:52 AM
BRIEF-Trovagene files for offering of up to $17.5 mln- SEC filingBRIEF-Trovagene files for offering of up to $17.5 mln- SEC filing
www.reuters.com - October 25 at 5:44 PM
Trovagene (TROV) Announces PLK1 Inhibitor (PCM-075 ... - StreetInsider.comTrovagene (TROV) Announces PLK1 Inhibitor (PCM-075 ... - StreetInsider.com
www.streetinsider.com - October 19 at 9:59 AM
TrovaGene, Inc. (TROV) PT Set at $4.00 by Maxim GroupTrovaGene, Inc. (TROV) PT Set at $4.00 by Maxim Group
www.americanbankingnews.com - October 18 at 3:08 PM
BRIEF-Trovagenes PCM-075 demonstrates Synergy with ZytigaBRIEF-Trovagene's PCM-075 demonstrates Synergy with Zytiga
www.reuters.com - October 18 at 9:46 AM
Trovagenes PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga® (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor CellsTrovagene's PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga® (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor Cells
finance.yahoo.com - October 18 at 9:46 AM
TrovaGene Inc (TROV) Officially Announces Orphan Drug Designation for PCM-075TrovaGene Inc (TROV) Officially Announces Orphan Drug Designation for PCM-075
finance.yahoo.com - October 11 at 8:51 AM
ETFs with exposure to TrovaGene, Inc. : October 10, 2017ETFs with exposure to TrovaGene, Inc. : October 10, 2017
finance.yahoo.com - October 11 at 8:51 AM
Trovagene (TROV) PLK1 Inhibitor, PCM-075, Granted FDA Orphan Drug DesignationTrovagene (TROV) PLK1 Inhibitor, PCM-075, Granted FDA Orphan Drug Designation
www.streetinsider.com - October 10 at 7:38 AM
FDA Grants Orphan Drug Designation to Trovagenes PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML)FDA Grants Orphan Drug Designation to Trovagene's PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML)
finance.yahoo.com - October 9 at 8:36 AM

SEC Filings

TrovaGene (NASDAQ:TROV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

TrovaGene (NASDAQ:TROV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

TrovaGene (NASDAQ TROV) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.